El interés en corto de Ovid Therapeutics da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Ovid Therapeutics. Los datos de interés en corto se actualizan cada dos semanas.

Ovid Therapeutics (NASDAQ:OVID) Bolsa, Informe de interés en corto

Ovid Therapeutics

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.

Ovid Therapeutics Inc

UBS analyst Douglas Harter maintains Granite Point Mortgage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPMT#NYSE">GPMT</a>) with a Buy and raises the price target from $3.5 to $4.

News

Price Target

Analyst Ratings

GPMT

UBS Maintains Buy on Granite Point Mortgage, Raises Price Target to $4

<a href="https://www.bloomberg.com/live/us" title="https://www.bloomberg.com/live/us">https://www.bloomberg.com/live/us</a>

Federal Reserve

Fed's Collins: Not Seeing Evidence Of New Inflation Pressures; The Job Market Looks Like Full Employment Conditions; Sees Healthy Labor Market Conditions; Doesn't See Big Urgency To Lower Rates, But Wants To Preserve Healthy Economy; Won't Speculate About What Trump Will Do On Economy; Tariffs Can Be A Driver Of Inflation

UBS analyst Alex Kramm maintains FactSet Research Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDS#NYSE">FDS</a>) with a Neutral and raises the price target from $485 to $525.

UBS Maintains Neutral on FactSet Research Systems, Raises Price Target to $525

WIIM

UUUU

Shares of uranium stocks are trading higher following a report suggesting Russia has imposed temporary restrictions on the export of enriched uranium to the US.

Janus Henderson Group plc Ordinary Shares

CORRECTION: Trian 13F Reported No Change In Shares In Janus Henderson Group And General Electric Co.

Whales with a lot of money to spend have taken a noticeably bearish stance on Rivian Automotive.
Looking at options history for Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) we detected 12 trades.
If we consider the specifics of each trade, it is accurate to state that 33% of the investors opened trades with bullish expectations and 50% with bearish.
From the overall spotted trades, 7 are puts, for a total amount of $846,969 and 5, calls, for a total amount of $266,288.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $2.5 to $20.0 for Rivian Automotive during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Rivian Automotive's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Rivian Automotive's whale activity within a strike price range from $2.5 to $20.0 in the last 30 days. 
<h3>Rivian Automotive Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731684912_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>RIVN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$1.07</td>
<td>$1.05</td>
<td>$1.06</td>
<td>$11.00</td>
<td>$349.0K</td>
<td>11.8K</td>
<td>3.7K</td>
</tr>
<tr>
<td>RIVN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$0.25</td>
<td>$0.24</td>
<td>$0.25</td>
<td>$7.50</td>
<td>$187.5K</td>
<td>56.7K</td>
<td>806</td>
</tr>
<tr>
<td>RIVN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$0.24</td>
<td>$0.23</td>
<td>$0.25</td>
<td>$10.00</td>
<td>$80.7K</td>
<td>21.3K</td>
<td>9.5K</td>
</tr>
<tr>
<td>RIVN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$1.24</td>
<td>$1.22</td>
<td>$1.23</td>
<td>$10.00</td>
<td>$79.4K</td>
<td>42.9K</td>
<td>1.1K</td>
</tr>
<tr>
<td>RIVN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$0.64</td>
<td>$0.4</td>
<td>$0.57</td>
<td>$10.50</td>
<td>$79.3K</td>
<td>20.9K</td>
<td>3.8K</td>
</tr>
</tbody>
</table>

<h3>About Rivian Automotive</h3>
Rivian Automotive Inc designs, develops, and manufactures category-defining electric vehicles and accessories. In the consumer market, the company launched the R1 platform with the first generation of consumer vehicles: the R1T, a two-row, five-passenger pickup truck, and the R1S, a three-row, seven-passenger sport utility vehicle (SUV).
In light of the recent options history for Rivian Automotive, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Rivian Automotive</h3>
<ul>
<li>Currently trading with a volume of 26,690,067, the RIVN's price is down by -4.07%, now at $9.89. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 96 days.</li>
</ul>
<h3>Professional Analyst Ratings for Rivian Automotive</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $14.8.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from RBC Capital has decided to maintain their Sector Perform rating on Rivian Automotive, which currently sits at a price target of $12. 
&#x2A; Consistent in their evaluation, an analyst from Guggenheim keeps a Buy rating on Rivian Automotive with a target price of $18. 
&#x2A; Maintaining their stance, an analyst from Mizuho continues to hold a Neutral rating for Rivian Automotive, targeting a price of $12. 
&#x2A; An analyst from Goldman Sachs persists with their Neutral rating on Rivian Automotive, maintaining a target price of $12. 
&#x2A; An analyst from Wedbush downgraded its action to Outperform with a price target of $20. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Rivian Automotive options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

RIVN

Market Whales and Their Recent Bets on RIVN Options

Deep-pocketed investors have adopted a bullish approach towards Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in PFE usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 20 extraordinary options activities for Pfizer. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 40% bearish. Among these notable options, 10 are puts, totaling $1,248,013, and 10 are calls, amounting to $924,906.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $15.0 to $30.0 for Pfizer over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Pfizer's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Pfizer's substantial trades, within a strike price spectrum from $15.0 to $30.0 over the preceding 30 days.
<h3>Pfizer Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731684907_0_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$1.88</td>
<td>$1.64</td>
<td>$1.7</td>
<td>$26.00</td>
<td>$340.0K</td>
<td>45.2K</td>
<td>2.1K</td>
</tr>
<tr>
<td>PFE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$1.63</td>
<td>$1.36</td>
<td>$1.4</td>
<td>$20.00</td>
<td>$283.2K</td>
<td>663</td>
<td>2.0K</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$6.25</td>
<td>$6.2</td>
<td>$6.2</td>
<td>$20.00</td>
<td>$256.6K</td>
<td>2.2K</td>
<td>2.0K</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$5.7</td>
<td>$5.6</td>
<td>$5.7</td>
<td>$20.00</td>
<td>$170.4K</td>
<td>1.7K</td>
<td>479</td>
</tr>
<tr>
<td>PFE</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$2.75</td>
<td>$2.63</td>
<td>$2.7</td>
<td>$25.00</td>
<td>$135.0K</td>
<td>35.4K</td>
<td>2.2K</td>
</tr>
</tbody>
</table>

<h3>About Pfizer</h3>
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Having examined the options trading patterns of Pfizer, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Pfizer Standing Right Now?</h3>
<ul>
<li>With a trading volume of 45,749,524, the price of PFE is down by -4.01%, reaching $24.98.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 74 days from now.</li>
</ul>
<h3>Expert Opinions on Pfizer</h3>
In the last month, 4 experts released ratings on this stock with an average target price of $36.75.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $45. 
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $45. 
&#x2A; In a cautious move, an analyst from Wolfe Research downgraded its rating to Underperform, setting a price target of $25. 
&#x2A; In a cautious move, an analyst from Bernstein downgraded its rating to Market Perform, setting a price target of $32. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Pfizer with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Unpacking the Latest Options Trading Trends in Pfizer

In one of the most significant cryptocurrency crime cases to date, Ilya Lichtenstein, who orchestrated the theft of 120,000 bitcoin from Bitfinex in 2016, was sentenced to <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40961791/the-biggest-crypto-crime-cases-in-2024-heists-frauds-and-multi-million-dollar-scams-shake-">five years in prison</a>.
The stolen Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), worth $71 million at the time, is now valued at over $7.6 billion. 
What Happened: Lichtenstein's elaborate laundering <a href="https://storage.courtlistener.com/recap/gov.uscourts.dcd.257739/gov.uscourts.dcd.257739.143.0.pdf">scheme</a>, carried out with the assistance of his wife, Heather Morgan, has been described by authorities as one of the most sophisticated money-laundering operations ever encountered in the cryptocurrency space.
U.S. District Judge Colleen Kollar-Kotelly, delivering the sentence on Thursday, called the theft "meticulously planned" and emphasized the importance of accountability. 
"It's important to send a message that you can't commit these crimes with impunity, that there are consequences to them," she said.
The hack targeted Hong Kong-based exchange Bitfinex, compromising 36% of the company's assets at the time. 
Prosecutors revealed that Lichtenstein spent months infiltrating Bitfinex's infrastructure to execute the theft. After the hack, he moved the stolen Bitcoin through a maze of transactions designed to obscure its origins. 
By 2022, the couple had successfully laundered around 21% of the stolen funds, worth $14 million at 2016 prices, and exceeding $1 billion in 2022.
Heather Morgan, who also faces sentencing, played a lower-level role, according to prosecutors.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/news/legal/24/11/41996491/18-republican-states-sue-bidens-sec-over-harsh-crypto-crackdown">18 Republican States Sue Biden&#8217;s SEC Over Harsh Crypto Crackdown</a>
Initially unaware of the full extent of her husband's actions, she later assisted in laundering the stolen funds.
Authorities recovered over 96% of the stolen bitcoin, valued at over $6 billion, thanks in part to Lichtenstein's cooperation following his arrest in February 2022. 
His defense attorney, Samson Enzer, highlighted this cooperation, stating, "The vast bulk of the stolen money was never spent."
The theft significantly impacted Bitfinex's operations and reputation, forcing the company to take swift action to protect its customers. 
"The hack devastated our finances and reputation," said Barry Berke, an attorney for Bitfinex. 
Despite the setback, Bitfinex absorbed the losses to shield its customers from the fallout.
While in custody, Lichtenstein expressed regret, stating, "I want to take full responsibility for my actions and make amends any way I can." 
He also shared his desire to contribute positively in the future by applying his skills to combat cybercrime.
What&#8217;s Next: The case highlights the need for robust regulatory frameworks and cybersecurity measures to protect digital asset markets, an issue that will be explored at Benzinga&#8217;s <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41993524/gary-gensler-hints-at-ending-his-stint-as-sec-chair-defends-crypto-regulation-agenda">Gary Gensler Hints At Ending His Stint As SEC Chair, Defends Crypto Regulation Agenda</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin Hacker Sentenced To 5 Years For Laundering Billions In Crypto Theft

HSPTU

Trading Halt: Halt status updated at 10:35:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation

Whales with a lot of money to spend have taken a noticeably bullish stance on Regeneron Pharmaceuticals.
Looking at options history for Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) we detected 8 trades.
If we consider the specifics of each trade, it is accurate to state that 25% of the investors opened trades with bullish expectations and 0% with bearish.
From the overall spotted trades, 4 are puts, for a total amount of $134,920 and 4, calls, for a total amount of $175,889.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $600.0 and $920.0 for Regeneron Pharmaceuticals, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Regeneron Pharmaceuticals's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Regeneron Pharmaceuticals's whale activity within a strike price range from $600.0 to $920.0 in the last 30 days. 
<h3>Regeneron Pharmaceuticals 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731684902_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$188.5</td>
<td>$179.3</td>
<td>$185.0</td>
<td>$600.00</td>
<td>$74.0K</td>
<td align="right">5</td>
<td align="right">4</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$155.0</td>
<td>$148.0</td>
<td>$151.0</td>
<td>$920.00</td>
<td>$45.3K</td>
<td align="right">161</td>
<td align="right">3</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$44.2</td>
<td>$38.0</td>
<td>$41.48</td>
<td>$760.00</td>
<td>$41.4K</td>
<td align="right">26</td>
<td align="right">10</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$12.0</td>
<td>$4.8</td>
<td>$8.57</td>
<td>$765.00</td>
<td>$34.2K</td>
<td align="right">0</td>
<td align="right">40</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$118.0</td>
<td>$113.0</td>
<td>$113.0</td>
<td>$850.00</td>
<td>$33.9K</td>
<td align="right">15</td>
<td align="right">3</td>
</tr>
</tbody>
</table>

<h3>About Regeneron Pharmaceuticals</h3>
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
In light of the recent options history for Regeneron Pharmaceuticals, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Regeneron Pharmaceuticals Standing Right Now?</h3>
<ul>
<li>With a trading volume of 189,761, the price of REGN is down by -2.09%, reaching $766.17.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 77 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Regeneron Pharmaceuticals</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $1127.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from RBC Capital downgraded its rating to Outperform, setting a price target of $1260. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on Regeneron Pharmaceuticals with a target price of $1065. 
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Overweight rating for Regeneron Pharmaceuticals, targeting a price of $1050. 
&#x2A; In a cautious move, an analyst from RBC Capital downgraded its rating to Outperform, setting a price target of $1260. 
&#x2A; Consistent in their evaluation, an analyst from Oppenheimer keeps a Outperform rating on Regeneron Pharmaceuticals with a target price of $1000. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Regeneron Pharmaceuticals with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

REGN

Check Out What Whales Are Doing With REGN

UBS maintains Enbridge (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ENB#TSX">ENB</a>) with a Buy and raises the price target from C$63 to C$68.

TSX:ENB

UBS Maintains Buy on Enbridge, Raises Price Target to C$68

RBC Capital analyst Arthur Nagorny maintains CCL Industries (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CCL#TSX">CCL</a>) with a Outperform and lowers the price target from C$92 to C$90.

TSX:CCL

TSX:CCL/B

RBC Capital Maintains Outperform on CCL Industries, Lowers Price Target to C$90

Truist Securities analyst Neal Dingmann maintains Targa Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRGP#NYSE">TRGP</a>) with a Buy and raises the price target from $175 to $225.

TRGP

Truist Securities Maintains Buy on Targa Resources, Raises Price Target to $225

Fed's Collins Says No Preset Path For Monetary Policy; Economy Is In A Very Good Place Right Now; Fed Policy Is Well Positioned; Won't Take A December Easing Off Table; Data Will Determine What Fed Does In December

RBC Capital analyst Maurice Choy maintains Canadian Utilities (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CU#TSX">CU</a>) with a Sector Perform and raises the price target from C$38 to C$39.

TSX:CU

RBC Capital Maintains Sector Perform on Canadian Utilities, Raises Price Target to C$39

Truist Securities analyst Neal Dingmann maintains Ovintiv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OVV#NYSE">OVV</a>) with a Buy and raises the price target from $57 to $59.

Truist Securities Maintains Buy on Ovintiv, Raises Price Target to $59

Editor's Note: The headline has been updated to reflect the article's content more accurately.
Super Micro Computer Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) is teetering on the edge of a dramatic pivot. Once a darling of Nvidia Corp's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) AI-driven success, the server manufacturer now finds itself grappling with a <a href="https://www.benzinga.com/quote/SMCI/news">slew of issues</a> that could determine its survival.
As Super Micro hurtles toward a Nasdaq delisting deadline, all eyes are on Nvidia's earnings next week to gauge whether Super Micro can steady its ship—or sink further into the abyss.
<h2 class="wp-block-heading">Nvidia's Shadow Looms Large</h2>
Supermicro's close ties with Nvidia have been both a blessing and a curse. 
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="628" height="456" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15071011/Screenshot-2024-11-15-at-5.39.54-PM.png" alt="" class="wp-image-650036" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15071011/Screenshot-2024-11-15-at-5.39.54-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15071011/Screenshot-2024-11-15-at-5.39.54-PM-300x218.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111524&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
Nvidia's dominance in AI chip innovation fueled a meteoric rise for SMCI stock, especially during the first quarter, but that relationship is now under scrutiny. 
Recent whispers suggest <a href="https://www.benzinga.com/trading-ideas/technicals/24/11/41745935/super-micro-computer-posts-q1-earnings-are-delisting-fears-here-to-stay-or-can-the-stock">Nvidia is diversifying its partnerships</a>, reportedly redirecting orders from Super Micro to other server vendors. While Nvidia hasn't officially confirmed these moves, the implications are clear: reputational and operational risks tied to Super Micro's ongoing crises might be too hot for Nvidia to handle.
Nvidia's earnings call on Nov. 20 could be the turning point for SMCI stock investors. If Nvidia acknowledges its cooling stance toward Super Micro, the already battered stock might face another wave of sell-offs. 
On the flip side, silence on the matter could offer Super Micro a temporary reprieve.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41970761/jim-cramer-says-super-micro-in-real-hot-water-as-stock-plunges-10-in-thursday-pre-market-after-falling-nearly-60-this-week">Jim Cramer Says Super Micro In &#8216;Real Hot Water&#8217; As Stock Plunges 10% In Thursday Pre Market After Falling Nearly 60% This Week</a>
<h2 class="wp-block-heading">SMCI Stock Potential Delisting Drama</h2>
Super Micro's troubles don't end with Nvidia. The company is racing against a Nov. 16 Nasdaq deadline to resolve its delinquent SEC filings, a fallout from the <a href="https://www.benzinga.com/news/24/09/41052423/super-micro-computer-stock-falls-on-report-of-doj-probe-what-to-know">ongoing accounting fiasco</a> sparked by Hindenburg Research's scathing short report. 
With its 10-K filing delayed, its 10-Q now also postponed, and its auditor Ernst &amp; Young resigning in October, the situation looks bleak.
If <a href="https://www.benzinga.com/trading-ideas/technicals/24/11/41745935/super-micro-computer-posts-q1-earnings-are-delisting-fears-here-to-stay-or-can-the-stock">the Nasdaq delisting</a> process kicks off, SMCI stock could lose access to critical ETFs and its spot in the S&amp;P 500, leaving it to trade over the counter. 
This downgrade could scare off institutional investors and trigger further downward momentum.
<h2 class="wp-block-heading">Nvidia&#8217;s Earnings &#8211; A Litmus Test For SMCI Stock Investors</h2>
Despite the doom and gloom, Super Micro isn't entirely out of moves. An independent <a href="https://www.ft.com/content/9e8eae65-8c29-4ab9-aea6-89e0a7a2f356">committee</a> has found no evidence of fraud among its management and plans to recommend remedial measures soon. If these measures, combined with a plausible compliance plan for Nasdaq, are compelling enough, Super Micro could buy itself more time to recover.
But even if SMCI clears these hurdles, regaining Nvidia's trust and rebuilding its credibility in the market won't be a walk in the park. 
For now, Nvidia's earnings report might be a forecast for the AI boom and a litmus test for Super Micro's survival. Investors should brace for a make-or-break week ahead.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/treasuries/24/11/41993899/powells-hawkish-remarks-shake-markets-stocks-fall-dollar-rockets-bitcoin-dips">Powell&#8217;s Hawkish Remarks Shake Markets: Stocks Fall, Dollar Rockets, Bitcoin Dips</a></li>
</ul>
Photo: Shutterstock

Tech

NVDA

SMCI

Why Super Micro's Future May Hinge On Nvidia Earnings, Nasdaq Deadline (UPDATED)

RBC Capital analyst Keith Mackey maintains Enerflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFXT#NYSE">EFXT</a>) with a Outperform and raises the price target from $9 to $12.

EFXT

RBC Capital Maintains Outperform on Enerflex, Raises Price Target to $12

UBS analyst Mauricio Serna maintains Dillard's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDS#NYSE">DDS</a>) with a Sell and raises the price target from $194 to $198.

UBS Maintains Sell on Dillard's, Raises Price Target to $198

Intuitive Machines Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) posted better-than-expected <a href="https://www.benzinga.com/general/space/24/11/41977504/intuitive-machines-stock-volatile-on-q3-earnings-what-you-need-to-know">third-quarter sales on Thursday</a>.
Intuitive Machines reported third-quarter revenue of $58.48 million, beating analyst estimates of $50.89 million, according to Benzinga Pro. Total revenue was up 359% on a year-over-year basis.
The company reported a net loss of $80.44 million, versus net income of $14.31 million in the prior year's quarter. Backlog grew to $316.2 million in the quarter, the highest in company history. Intuitive Machines ended the quarter with $89.6 million in cash.
"Intuitive Machines had a very strong third quarter highlighted by key wins, revenue growth, and the largest cash balance in Company history," said Steve Altemus, CEO of Intuitive Machines.
Intuitive Machines narrowed its full-year revenue outlook to a range of $215 million to $235 million. The company also said it expects continued backlog expansion driven by potential upcoming awards including Near Space Network 1.2 / 1.3 Direct to Earth and LTVS Phase 2, as well as task orders for OMES and Near Space Network 2.2.
Intuitive Machines shares gained 12.8% to trade at $11.55 on Friday.
These analysts made changes to their price targets on Intuitive Machines following earnings announcement.
<ul>
<li>Benchmark analyst Josh Sullivan maintained Intuitive Machines with a Buy and raised the price target from $10 to $16.</li>
<li>Cantor Fitzgerald analyst Andres Sheppard maintained the stock with an Overweight and raised the price target from $10 to $15.</li>
<li>Canaccord Genuity analyst Austin Moeller maintained Intuitive Machines with a Buy and raised the price target from $11 to $12.5.</li>
</ul>
Considering buying LUNR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="415" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15102805/image-173-1024x415.png" alt="" class="wp-image-650524" style="width:585px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15102805/image-173-1024x415.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15102805/image-173-300x122.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15102805/image-173-768x312.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15102805/image-173-1536x623.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15102805/image-173.png 1617w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42008196/jim-cramer-says-this-tobacco-stock-is-undervalued-but-hes-not-recommending-it">Jim Cramer Says This Tobacco Stock Is &#8216;Undervalued&#8217; But He&#8217;s Not Recommending It</a></li>
</ul>

Earnings

Trading Ideas

LUNR

These Analysts Boost Their Forecasts On Intuitive Machines Following Q3 Earnings

Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome

Ovid Therapeutics ( ($OVID) ) has issued an announcement. Ovid Therapeutics Inc. has promoted Margaret "Meg" Alexander to President and COO, recogn...

Ovid Therapeutics Elevates Meg Alexander to President and COO

BTIG analyst Thomas Shrader maintained a Buy rating on Ovid Therapeutics (OVID – Research Report) yesterday and set a price target of $5.00. Thomas...

Promising Neurology Breakthrough: Ovid Therapeutics' OV329 Shows Safety and Efficacy Potential

Oppenheimer analyst Francois Brisebois maintained a Hold rating on Ovid Therapeutics (OVID – Research Report) today. The company's shares closed ye...

Oppenheimer Sticks to Their Hold Rating for Ovid Therapeutics (OVID)

H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on OVID stock, giving a Buy rating on September 27. Ram Selvaraju has giv...

Buy Rating Affirmed for Ovid Therapeutics on Promising Safety Profile and Robust Pipeline Progress

Thomas Shrader, an analyst from BTIG, maintained the Buy rating on Ovid Therapeutics (OVID – Research Report). The associated price target remains ...

Ovid Therapeutics: Promising Safety Profile and Growth Potential Underpin Buy Rating

Reports Q3 revenue $173,000, consensus $90k. "The biopharmaceutical industry is entering an exciting new era of neurotherapeutics, and we are poise...

Ovid Therapeutics reports Q3 EPS (20c), consensus (20c)

Ovid Therapeutics GAAP EPS of -$0.20 misses by $0.01, revenue of $0.17M beats by $0.1M

Ritu Baral, an analyst from TD Cowen, has initiated a new Buy rating on Ovid Therapeutics (OVID). Ritu Baral has given his Buy rating due to a comb...

Ovid Therapeutics: Strategic Developments and Financial Stability Lead to Buy Rating

Wedbush analyst Laura Chico maintained a Buy rating on Ovid Therapeutics (OVID – Research Report) today and set a price target of $4.00. The compan...

Comments

Ovid Therapeutics

Interés en corto

Ovid Therapeutics (NASDAQ:OVID) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL